Image

    Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib

    Jiangxia Huang, Ougen Liu
    Studysummary This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Efficacy and Safety of Baricitinib in Patients With Refractory Alopecia Areata Dermatologic Therapy · 2022
    2. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022

    Related research 5

    1. Case Report of Novel Combination of Anthralin and Calcipotriene Leading to Trichologic Response in Alopecia Areata JAAD case reports · 2019
    2. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    3. Linear Alopecia Areata JAAD case reports · 2018
    4. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018
    5. Topical Minoxidil for the Treatment of Alopecia Areata PubMed · 2017